caa a22 4500 469121866 CHVBK 20180323133141.0 cr unu---uuuuu 170328e19920401xx s 000 0 eng 10.1007/BF02244819 doi (NATIONALLICENCE)springer-10.1007/BF02244819 Actions and some interactions of 5-HT1A ligands in the elevated X-maze and effects of dorsal raphe lesions [Elektronische Daten] [M. Critchley, K. Njung'e, Sheila Handley] Effects of 5-HT1A agonists and partial agonists on open/total arm entry ratio (OTR) have been examined in the elevated X-maze anxiety model. 8-OH-DPAT (0.05-0.2 mg/kg), RU 24969 (0.5-2.0 mg/kg) and BAY R 1521 (0.1-1.2 mg/kg) produced dose-dependent reductions in OTR, signifying anxiogenic effects. Buspirone reduced OTR only at doses (0.25-5.0 mg/kg) decreasing total entries; gepirone (0.1-5.0 mg/kg) was inactive. Ipsapirone (0.25-5.0 mg/kg) increased OTR and at 1.0 mg/kg antagonised the anxiogenic action of 8-OH-D-PAT, RU 24969 and BAY R 1531. Gepirone (2.5 mg/kg) failed to antagonise 8-OH-DPAT, but the dose was limited by its effect on total entries. The anxiogenic effect of a low dose of 8-OH-DPAT was also prevented byp-chlorophenylalanine (p-CPA) pretreatment and reversed to anxiolytic by 5,7-dihydroxytryptamine lesions of dorsal raphe, which spared median raphe. These lesions also abolished the anxiolytic effect of ipsapirone without affecting the anxiogenic response to yohimbine. This study provides preliminary evidence that 8-OH-DPAT may be capable of acting as an agonist and ipsapirone as an antagonist at a presynaptic site related to dorsal raphe which is separate from the site of action of yohimbine. 5-HT1A agonists and partial agonists may have multiple sites and/or mechanisms of action in the elevated X-maze. Springer-Verlag, 1992 Elevated X-maze nationallicence Anxiety nationallicence 5-HT1A receptors nationallicence Critchley M. Pharmacology Department, Wellcome Research Laboratories, Beckenham, Kent, UK aut Njung'e K. Kenya Medical Research Institute, P.O. Box 54840, Nairobi, Kenya, South Africa aut Handley Sheila Pharmacology Research, Pharmaceutical Sciences Institute, Aston University, B4 7ET, Birmingham, UK aut Psychopharmacology Springer-Verlag 106/4(1992-04-01), 484-490 0033-3158 106:4<484 1992 106 213 https://doi.org/10.1007/BF02244819 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244819 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Critchley M. Pharmacology Department, Wellcome Research Laboratories, Beckenham, Kent, UK aut NATIONALLICENCE 700 1- Njung'e K. Kenya Medical Research Institute, P.O. Box 54840, Nairobi, Kenya, South Africa aut NATIONALLICENCE 700 1- Handley Sheila Pharmacology Research, Pharmaceutical Sciences Institute, Aston University, B4 7ET, Birmingham, UK aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 106/4(1992-04-01), 484-490 0033-3158 106:4<484 1992 106 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer